Overview

Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A

Status:
Recruiting
Trial end date:
2028-02-01
Target enrollment:
Participant gender:
Summary
Open label, single arm, multicenter phase II trial.
Phase:
Phase 2
Details
Lead Sponsor:
French Innovative Leukemia Organisation
Treatments:
Venetoclax